Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2% - Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) fell 5.2% during trading on Tuesday . The stock traded as low as $17.53 and last traded at $17.47. 146,819 shares were traded during trading, a decline of 46% from the average session volume of 273,303 shares. The stock had previously closed at $18.42.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DNTH. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Guggenheim reaffirmed a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Robert W. Baird cut their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Stock Performance

The firm has a market capitalization of $560.23 million, a price-to-earnings ratio of -6.97 and a beta of 1.48. The company has a fifty day moving average of $18.95 and a two-hundred day moving average of $21.42.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.04. The business had revenue of $1.16 million during the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. SG Americas Securities LLC lifted its holdings in Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock worth $210,000 after purchasing an additional 814 shares during the last quarter. KBC Group NV bought a new position in Dianthus Therapeutics during the 4th quarter worth $35,000. R Squared Ltd bought a new position in Dianthus Therapeutics during the 4th quarter worth $26,000. Rhumbline Advisers increased its stake in Dianthus Therapeutics by 3.8% during the 4th quarter. Rhumbline Advisers now owns 35,933 shares of the company's stock worth $783,000 after acquiring an additional 1,316 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Dianthus Therapeutics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock worth $3,641,000 after acquiring an additional 1,092 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.